Lung gene therapy: Clinical and regulatory issues

Aniruddha C. Amrite, Narayan P.S. Cheruvu, Sneha Sundaram, Rajagopal N. Aravalli, Pi Wan Cheng, Uday B. Kompella

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Lung gene therapy is a promising therapeutic approach for several difficult to treat disorders such as cystic fibrosis, α1-antitrypsin deficiency, and cancers. Although several gene therapy protocols have proven success in preclinical studies, when moved to the clinical stages, they have met with limited success. Thus, there is a need to carefully assess the developmental approaches undertaken with gene therapy products intended for lung disorders. This review summarizes the advances made in lung gene therapy, discusses the limitations of the existing approaches including the lack of reliability of preclinical studies, immunogenecity and toxicity of the gene therapy vectors, and the poor efficiency of nonviral vectors, and invokes the role of ethics and the regulatory agencies in better developing the gene therapy products.

Original languageEnglish (US)
Pages (from-to)1-28
Number of pages28
JournalClinical Research and Regulatory Affairs
Issue number1
StatePublished - 2004

Bibliographical note

Funding Information:
National Institutes of Health (NIH) Overview


  • FDA
  • Immunogenicity
  • Lung gene therapy
  • Nonviral vectors
  • Toxicity
  • Viral vectors


Dive into the research topics of 'Lung gene therapy: Clinical and regulatory issues'. Together they form a unique fingerprint.

Cite this